Kelleher Financial Advisors Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Kelleher Financial Advisors trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,029 shares of the biopharmaceutical company’s stock after selling 215 shares during the quarter. Kelleher Financial Advisors’ holdings in Gilead Sciences were worth $742,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Public Sector Pension Investment Board lifted its stake in Gilead Sciences by 72.9% during the second quarter. Public Sector Pension Investment Board now owns 47,722 shares of the biopharmaceutical company’s stock worth $3,274,000 after purchasing an additional 20,120 shares during the last quarter. Marshall Wace LLP bought a new stake in Gilead Sciences during the second quarter worth about $8,269,000. Mill Creek Capital Advisors LLC bought a new stake in Gilead Sciences during the second quarter worth about $205,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in Gilead Sciences by 60.1% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 238,870 shares of the biopharmaceutical company’s stock worth $16,389,000 after purchasing an additional 89,632 shares during the last quarter. Finally, Insigneo Advisory Services LLC lifted its stake in Gilead Sciences by 1.7% during the second quarter. Insigneo Advisory Services LLC now owns 8,830 shares of the biopharmaceutical company’s stock worth $661,000 after purchasing an additional 148 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GILD shares. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. UBS Group boosted their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Bank of America reissued a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a research note on Tuesday, December 10th. Daiwa America raised Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Finally, Piper Sandler boosted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $97.96.

Insider Activity

In related news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 over the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.1 %

Shares of GILD stock opened at $93.04 on Thursday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market capitalization of $115.95 billion, a PE ratio of 1,033.78, a PEG ratio of 1.31 and a beta of 0.18. The stock has a fifty day simple moving average of $91.62 and a two-hundred day simple moving average of $84.57.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the business posted $2.29 EPS. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. On average, analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.